About the study
EXHALE-4 is a Phase 3 study evaluating dexpramipexole, an investigational once-daily oral medicine, as an add-on to usual asthma treatment in people with eosinophilic asthma, a type of asthma linked to high levels of eosinophils (a kind of white blood cell). The study looks at lung function, asthma control and quality of life over 24 weeks, along with safety.
Who took part
The study enrolled people who:
- Were 12 years of age or older
- Had a doctor's diagnosis of asthma for at least 12 months
- Used a daily inhaled steroid plus at least one other controller medicine
Status at Veritas
This study is active but no longer enrolling new participants. People already enrolled continue their study visits.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT05748600).